- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -
- Data presented in a platform session at the Annual Meeting of the
The study is authored by
“PIRA is a condition that poses a major unmet need for patients with multiple sclerosis,” stated
“We do not have any recognized approaches to try to alter microglial activation at present, which everyone agrees at this point in time is relevant throughout the life of a patient with MS. Even ocrelizumab [Ocrevus] for primary progressive MS has modest impact, so the potential here is great, and the proof of principle that you can alter the microglia is a real punchline,” said
The study assesses the effect of intranasal foralumab on microglial activation in na-SPMS patients with PIRA as measured by positron emission tomography (PET) imaging via radiology marker [F-18]PBR06-PET, a novel, long-half-life ligand used in PET scanning. The study is designed to be open-label and is based on data from the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway. In this study, five of six patients (83%, 95% confidence interval 44%-97%) showed a qualitative reduction on [F-18]PBR06-PET in multiple brain regions after both 3 and 6 months of nasal foralumab treatment.
Data from the study was presented at a platform session at the Annual Meeting of the
The link to the full Neurology Today® article can be found here: https://journals.lww.com/neurotodayonline/blog/NeurologyTodayConferenceReportersAANAnnualMeeting/pages/post.aspx?PostID=211
About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[2],[3]
About
For further inquiries:
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
646.970.4681
ikoffler@lifesciadvisors.com
[1] Muller, M.D., J., Cagol, M.D., A., Lorschieder, M.D., J.; Harmonizing Definitions for Progressions Independent of Relapse Activity and Multiple Sclerosis: JAMA Neurol. 2023;80(11):1232-1245. doi:10.1001/jamaneurol.2023.3331
[2] https://www.pnas.org/doi/10.1073/pnas.2220272120
[3] https://www.pnas.org/doi/10.1073/pnas.2309221120
Source:
2024 GlobeNewswire, Inc., source